Effect of meglumine acridonacetate on growth of experimental colon adenocarcinoma and tumor-associated changes in the blood of BALB/c mice

  • A. P. Trashkov B.P. Konstantinov Petersburg Institute of Nuclear Physics, Gatchina, Russia; I.M. Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences, St. Petersburg, Russia
  • A. L. Kovalenko Institute of Toxicology of the Federal Biomedical Agency of Russia, St. Petersburg, Russia
  • E. I. Dragomiretskaya B.P. Konstantinov Petersburg Institute of Nuclear Physics, Gatchina, Russia
  • Ya. D. Barakov I.M. Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences, St. Peterburg, Russia
  • M. G. Khotin Institute of Cytology of the Russian Academy of Science, St. Petersburg, Russia http://orcid.org/0000-0002-8293-6368
  • A. V. Kalatanova B.P. Konstantinov Petersburg Institute of Nuclear Physics, St. Petersburg, Russia
  • A. A. Kravtsova B.P. Konstantinov Petersburg Institute of Nuclear Physics, Gatchina, Russia
  • E. A. Pushkina B.P. Konstantinov Petersburg Institute of Nuclear Physics, Gatchina, Russia
  • A. G. Vasiliev B.P. Konstantinov Petersburg Institute of Nuclear Physics, Gatchina, Russia
DOI: https://doi.org/10.25557/2310-0435.2019.02.51-61
Keywords: meglumine acridonacetate, tumor, CAC, cyclophosphane, colorectal cancer, blood cells, antitumor therapy

Abstract

Growing malignant tumors exert a pronounced toxic effect on all organs and tissues. Thereby, they contribute to various concomitant pathology, change the treatment tactics, and aggravate prognosis for the disease. The treatment itself, specifically a cytotoxic therapy, may also worsen the associated pathology and provoke exacerbation of chronic conditions. These factors determine a need for complex assessment of the drugs used in oncology, both regarding their effect on the neoplasm and side effects on functioning of vital organ systems. Aim: Complex evaluation of the effect of a candidate antitumor drug, meglumine acridonacetate, on experimental tumor growth and the blood system, including the effect on the background of cytostatic therapy. Material and methods. The study was performed on 256 male BALB/c mice. Colon adenocarcinoma (CAC) was used as an experimental model of tumor growth. The experimental chemotherapy with cyclophosphane (175 mg/kg) was administered on days 2 and 5 of tumor implantation. Meglumine acridonacetate (100 mg/kg) was administered daily for 5 days after the CAC implantation. The studied parameters included the tumor growth rate and metastatic activity. Clinical blood tests were also performed. Results. Cyclophosphane exerted a pronounced inhibitory effect on the growth of CAC primary node and tumor dissemination. The cytotostatic therapy produced a severe but brief hemotoxic effect. Addition of meglumine acridonacetate to the experimental treatment plan potentiated the therapeutic effect of cyclophosphane and considerably compensated for its hemotoxic effect. The monotherapy with meglumine acridonacetate significantly inhibited CAC metastasis and stimulated hematopoiesis. Conclusion: Supplementation of the cyclophosphane treatment plan with meglumine acridonacetate enhanced the cytostatic efficacy and improved its safety with respect of the blood system. The meglumine acridonacetate monotherapy exerted a moderate therapeutic effect on tumor growth and a clinically significant inhibitory effect on tumor metastasis.

Published
2019-06-04
How to Cite
Trashkov, A. P., Kovalenko, A. L., Dragomiretskaya, E. I., Barakov, Y. D., Khotin, M. G., Kalatanova, A. V., Kravtsova, A. A., Pushkina, E. A., & Vasiliev, A. G. (2019). Effect of meglumine acridonacetate on growth of experimental colon adenocarcinoma and tumor-associated changes in the blood of BALB/c mice. Patogenez (Pathogenesis), 17(2), 51-61. https://doi.org/10.25557/2310-0435.2019.02.51-61
Issue
Vol. 17 No. 2 (2019): Pathogenesis
Section
Experimental researches